The amyloid-beta project is to be filed for Alzheimer’s, and Biogen’s market cap regains the $15bn it lost in March.
Zolgensma’s impressive early sales figures spur hopes that gene therapy could finally be coming of age.
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Sage's big depression readout looms, while Biogen hopes for a mid-stage hit in lupus.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?